Opportunity Information: Apply for PAR 14 087
Apply for PAR 14 087
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (P01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.396 Cancer Biology Research.
- This funding opportunity was created on Feb 4, 2014 and posted on Feb 4, 2014.
- Applicants must submit their applications by Dec 14, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Special district governments Independent school districts Public housing authorities/Indian housing authorities City or township governments County governments Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses For profit organizations other than small businesses Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This opportunity, PAR-14-087, is a National Institutes of Health (NIH) Funding Opportunity Announcement for revision applications to existing NIH Program Project Grants (P01). It is not a brand-new standalone P01 competition. Instead, it is designed for investigators who already hold an active NIH P01 award and want to expand the scientific scope of that parent program through the addition of one or more new specific aims. The mechanism is a grant, the category is discretionary, and the scientific area is cancer biology research (CFDA 93.396). There is no cost sharing or matching requirement.
The scientific focus is metabolic reprogramming as a way to improve cancer immunotherapy. The FOA is looking for collaborative, multi-project efforts that deepen the mechanistic understanding of how metabolism shapes anti-tumor immunity in living systems, not just in simplified in vitro setups. A central theme is clarifying which metabolic processes enable immune cells to mount strong and durable anti-tumor responses in vivo, and identifying the metabolic constraints that prevent immune cells from functioning effectively once they enter tumors. In practical terms, the research is expected to address how nutrients, oxygen levels, signaling metabolites, and competition for metabolic resources in the tumor microenvironment influence immune effector functions such as proliferation, cytotoxic killing, cytokine production, persistence, and memory formation. Another explicit goal is to translate those mechanistic insights into actionable strategies: using the information to manipulate or reprogram metabolic pathways used by the tumor, the immune system, or both, with the end objective of improving the effectiveness of cancer immunotherapies.
Because the announcement is for P01 revisions, the expectation is that applicants will propose an integrated expansion to an already funded and functioning program project. The revision should add new aims that fit the FOA topic and strengthen the overall program through collaboration across projects and cores, rather than simply extending an existing line of work with incremental experiments. In other words, the NIH intent is to stimulate coordinated research that connects metabolic biology with tumor immunology in a way that is more powerful than separate, single-lab efforts, and that can generate a clearer causal and mechanistic picture of what is happening metabolically in tumors and immune cells during therapy.
Eligibility is broad across U.S.-based organizations that can hold NIH grants, including public and private institutions of higher education, nonprofits (including 501(c)(3) and non-501(c)(3) organizations), small businesses, and for-profit entities other than small businesses, as well as various levels of government (state, county, city/township, special district) and certain housing authorities. The FOA also explicitly notes eligibility categories such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISI institutions, among others. Non-U.S. (foreign) institutions are not eligible to apply as applicant organizations, but foreign components are allowed under NIH policy, and non-domestic components of U.S. organizations may participate. As with any revision mechanism, a key practical eligibility requirement is that the submitting team must have an active NIH P01 award to revise.
Key dates show the FOA was posted and created on February 4, 2014, with an original and current closing date of December 14, 2016. The archive date is January 14, 2017, indicating the announcement is no longer active for new submissions under that specific FOA number. For historical reference and full details, the NIH provided the official link to the announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-14-087.html (spacing in the source text aside, the NIH guide page is the authoritative source). For access issues or linking problems, the contact listed is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
In plain terms, this FOA supported add-on, collaborative research within existing P01 programs to figure out how metabolic conditions in and around tumors help or hinder immune attack, and then use that knowledge to redesign or augment immunotherapy strategies by targeting metabolism in tumor cells, immune cells, or both.
FAQs: NIH FOA PAR-14-087 (P01 Revision) - Metabolic Reprogramming to Improve Cancer Immunotherapy
1) What is PAR-14-087?
PAR-14-087 is a National Institutes of Health (NIH) Funding Opportunity Announcement (FOA) that supported revision applications to existing NIH Program Project Grants (P01). It was not a new, standalone competition for a brand-new P01. The intent was to let current P01 awardees expand the scientific scope of an already funded program by adding one or more new specific aims aligned with the FOA topic.
2) Is this a brand-new P01 funding opportunity?
No. This FOA was specifically for revisions to an active NIH P01. Applicants needed to already hold an active P01 award and submit an integrated expansion to that parent program.
3) What type of application did this FOA support?
This FOA supported revision applications that add new specific aims to an existing P01 program project. The revision was expected to strengthen and expand the overall program through collaboration across projects and cores, rather than simply continuing existing work with incremental experiments.
4) What is the scientific focus of PAR-14-087?
The scientific focus is metabolic reprogramming to improve cancer immunotherapy. The FOA sought research that clarifies how metabolism shapes anti-tumor immune responses in living systems and uses those mechanistic insights to improve immunotherapy strategies.
5) What disease or research area does this FOA fall under?
The FOA is in the area of cancer biology research, specifically linking tumor metabolism with tumor immunology to improve therapeutic immune responses.
6) What CFDA number is associated with this opportunity?
The opportunity is associated with CFDA 93.396.
7) What was NIH looking for scientifically (in plain language)?
NIH was looking for coordinated, collaborative work that explains how the metabolic conditions inside and around tumors affect the ability of immune cells to attack cancer, and how that knowledge can be used to adjust or redesign immunotherapies by targeting metabolism in tumor cells, immune cells, or both.
8) Why did the FOA emphasize in vivo (living system) research?
The FOA emphasized understanding metabolism and immunity in living systems rather than relying only on simplified in vitro setups. The goal was to generate a clearer causal and mechanistic picture of what is happening metabolically in tumors and immune cells during therapy, in conditions that better reflect real tumor biology.
9) What kinds of metabolic factors in the tumor microenvironment were highlighted?
The FOA highlighted how factors such as nutrients, oxygen levels, signaling metabolites, and competition for metabolic resources in the tumor microenvironment can shape immune performance against tumors.
10) What immune cell functions were specifically mentioned as being influenced by metabolism?
The FOA explicitly mentioned immune effector functions including proliferation, cytotoxic killing, cytokine production, persistence, and memory formation as important outcomes that may be affected by metabolic conditions in tumors.
11) What kinds of outcomes or deliverables did NIH want from the mechanistic work?
Beyond mechanistic understanding, NIH wanted the work to translate into actionable strategies for improving immunotherapy. This included developing approaches to manipulate or reprogram metabolic pathways used by the tumor, the immune system, or both, with the goal of making cancer immunotherapies more effective.
12) What does NIH mean here by a "collaborative, multi-project" effort?
In the context of a P01, the FOA emphasized an integrated program where multiple projects and cores work together on a shared scientific theme. The revision was expected to add aims that strengthen the overall program through collaboration, rather than separate, disconnected efforts.
13) Can an applicant propose incremental extensions of existing aims?
The FOA indicated that the revision should not be merely incremental. The expectation was to add new aims that fit the FOA topic and meaningfully expand the program's scope and collaborative impact.
14) Who was eligible to apply as an organization?
Eligibility was broad across U.S.-based organizations that can hold NIH grants, including:
- Public and private institutions of higher education
- Nonprofits (including 501(c)(3) and non-501(c)(3) organizations)
- Small businesses
- For-profit entities (other than small businesses)
- State, county, city/township, and special district governments
- Certain housing authorities
15) Did the FOA mention specific institution types (for example, MSIs)?
Yes. The FOA explicitly noted eligibility categories that include, among others, HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISI institutions.
16) Are foreign (non-U.S.) institutions eligible to apply as the applicant organization?
No. Non-U.S. (foreign) institutions were not eligible to apply as the applicant organization under this FOA.
17) Are foreign components allowed?
Yes. While foreign institutions could not apply as the main applicant organization, the FOA stated that foreign components are allowed under NIH policy, and non-domestic components of U.S. organizations may participate.
18) What is the key practical eligibility requirement for an application under this FOA?
Because this was a revision mechanism, the submitting team needed to have an active NIH P01 award to revise. The FOA was designed specifically for expanding an already funded and functioning P01 program.
19) What is the funding mechanism and category?
The mechanism is a grant, and the category is discretionary.
20) Was there a cost sharing or matching requirement?
No. The FOA stated there was no cost sharing or matching requirement.
21) When was this FOA posted and when did it close?
The FOA was posted/created on February 4, 2014. The original and current closing date listed was December 14, 2016.
22) Is PAR-14-087 still active?
No. The FOA has an archive date of January 14, 2017, indicating it is no longer active for new submissions under that specific FOA number.
23) Where is the official FOA announcement page?
The official NIH guide page for this FOA is: http://grants.nih.gov/grants/guide/pa-files/PAR-14-087.html
24) Who is the contact for access issues or linking problems?
The contact listed for access issues or linking problems is the NIH Office of Extramural Research (OER) webmaster: FBOWebmaster@OD.NIH.GOV
25) What was the overall purpose of this FOA?
In practical terms, the FOA supported add-on research within existing P01 programs to understand how metabolic conditions in and around tumors help or hinder immune attack, and to use that understanding to improve cancer immunotherapy by targeting metabolism in tumor cells, immune cells, or both.
Browse more opportunities from the same category: Education Health
Next opportunity: Low Temperature Geothermal Mineral Recovery Program
Previous opportunity: Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (U01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 087
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 087) also looked into and applied for these:
| Funding Opportunity |
|---|
| Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 15 005 Funding Number: RFA DA 15 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV Infection of the Central Nervous System (R01) Apply for PA 14 094 Funding Number: PA 14 094 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Eradication of HIV 1 from Central Nervous System Reservoirs (R01) Apply for PA 14 095 Funding Number: PA 14 095 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization Apply for RFA CA 14 002 Funding Number: RFA CA 14 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| NIDA Avant Garde Award Program for HIV/AIDS and Drug Use Research (DP1) Apply for RFA DA 15 004 Funding Number: RFA DA 15 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development of Software and Analysis Methods for Biomedical Big Data in Targeted Areas of High Need (U01) Apply for RFA HG 14 020 Funding Number: RFA HG 14 020 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Phase Clinical Trials in Imaging and Image Guided Interventions (R21) Apply for PAR 14 013 Funding Number: PAR 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Family Centered Self Management of Chronic Conditions (R21) Apply for PA 14 113 Funding Number: PA 14 113 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Family Centered Self Management of Chronic Conditions (R01) Apply for PA 14 112 Funding Number: PA 14 112 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21) Apply for PAR 14 105 Funding Number: PAR 14 105 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03) Apply for PAR 14 104 Funding Number: PAR 14 104 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01) Apply for PAR 14 106 Funding Number: PAR 14 106 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Additional Research Training Slots for NIDA Supported NRSA Institutional Training (T32) Grants (Admin Supp) Apply for PAR 14 115 Funding Number: PAR 14 115 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01) Apply for PAR 14 116 Funding Number: PAR 14 116 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Accelerating Improvements in the HIV Care Continuum (R01) Apply for PA 14 132 Funding Number: PA 14 132 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34) Apply for PA 14 135 Funding Number: PA 14 135 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21) Apply for PA 14 136 Funding Number: PA 14 136 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01) Apply for PA 14 137 Funding Number: PA 14 137 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Research (CPAR) (R21) Apply for PA 14 141 Funding Number: PA 14 141 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Community Partnerships to Advance Research (CPAR) (R01) Apply for PA 14 142 Funding Number: PA 14 142 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 087", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.